BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Oct 25, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Lamivudine/zidovudine regulatory update

FDA granted tentative marketing approval for Strides' lamivudine/zidovudine for use in combination with other antiretrovirals to treat HIV-1 infection. The...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >